|
|
 |
 |
|
Wendy S. Johnson
President and Chief Executive Officer
|
 |
Ms. Johnson has been a Venture Partner at ProQuest Investments since November 2005. Prior to joining ProQuest, she served as Senior Vice President, Corporate Development, at Salmedix Inc., where she led the effort to license their lead cancer therapeutic; the company was successfully sold to Cephalon in June 2005. Ms. Johnson has additional experience with device, diagnostic and drug discovery and development and regulatory affairs. She held senior business and corporate development positions at Women First, Prizm Pharmaceuticals (currently Selective Genetics Inc.), Cytel Corp., Symbiotics Corp., and Murex Corp. (Cambridge U.K.). Additionally, Ms. Johnson served as Assistant Director with the Center for Devices and Radiological Health at the Food and Drug Administration. Ms. Johnson holds an M.B.A. from Loyola University, an M.S. in Clinical Microbiology from the Hahnemann Medical School and a B.S. in Microbiology from the University of Maryland. |
Gary T. Elliott RPh, PharmD, Ph.D.
Executive Vice President, Product Development
|
 |
Dr. Elliott was vice president, product development at Salmedix, Inc. from July 2002 until its acquisition by Cephalon, Inc. in June 2005. Dr. Elliott served as Director and later as Senior Director, Product Development at Corixa Corporation, a biotechnology company, from November 1999 to June 2002. From November 1994 to November 1999, he held the position of Vice President, Pharmaceutical Development at RibiImmunoChem (Ribi), a biotechnology company acquired by Corixa Corporation. Earlier in his career, Dr. Elliott was an Assistant Professor of Pharmaceutical Sciences at the Medical Sciences Center, University of Arkansas in Little Rock. He received his B.S. in Pharmacy from Union University/Albany College of Pharmacy in Albany, New York, and his Doctorate in Clinical Pharmacy and Ph.D. in Pharmaceutical Sciences from University of Florida in Gainesville. |
Mark W. Surber, Ph.D.
Senior Director, Product Development
|
 |
As Senior Director, Product Development Dr. Surber is responsible for formulation and manufacturing design, intellectual property, and execution and oversight of the company's preclinical and clinical development efforts. Prior to joining Aires, Dr. Surber was a founder of Mpex Pharmaceuticals, where he later served as Director, Pharmaceutical Development. Prior to Mpex, Dr. Surber served at IGEN where he designed and coordinated several projects developing device-related clinical applications. He received his Ph.D. in Microbiology from the University of Illinois and B.S. in Medical Microbiology from California State University at Long Beach. |
Julie A. Crawford
Director, Finance and Administration
|
 |
Ms. Crawford was Director, Finance and Administration at Salmedix, Inc. from October 2001 until its acquisition by Cephalon, Inc. in June 2005, and continued her responsibilities through the transition and close of operations in San Diego in December 2005. During 2006, she served as a consultant to Cabrellis Pharmaceuticals, Inc., where she established and managed essential administrative systems and the finance and accounting role for this start-up company, which was acquired by Pharmion, Inc. in November of that year. From its inception in 1987 to 1995, Ms. Crawford served as an independent contractor in a similar role for Corvas International, Inc. and from 1990 to 2000 she also served as accounting consultant for several other early-stage technology companies, including Canji, Inc. She holds an M.B.A. from the University of Chicago Graduate School of Business and a B.A. in Economics from the University of Wisconsin – Madison. |
|
|
Our Team